-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Compilenewborn
Recently, Ocular Therapeutix announced that the U.
Dextenza is a preservative-free lacrimal insert that releases the corticosteroid dexamethasone in a dose of 0.
It is worth mentioning that Dextenza is the first small tube insert approved by the FDA.
Dextenza was originally approved in December 2018 for the treatment of eye pain after eye surgery
Allergic conjunctivitis is a common eye disease, and topical steroids are an important part of the clinical treatment of this disease
The efficacy and safety of Dextenza in the treatment of allergic conjunctivitis-related ocular itching have been confirmed in 3 randomized, multi-center, double-blind, parallel group, and vehicle-controlled studies
In all three trials, Dextenza exhibited a low mean ocular itching score at all time points during the 30-day study period
It has been observed that Dextenza has good safety and is generally well tolerated in clinical populations with allergic conjunctivitis and ocular inflammation and pain
In the pooled analysis of allergic conjunctivitis studies, the most common ocular adverse events were: increased intraocular pressure (3%), increased tearing (1%), ocular secretions (1%), and decreased vision (1%)
Reference source:
Ocular Therapeutix Announces FDA Approval of Supplemental New Drug Application (sNDA) for DEXTENZA (dexamethasone ophthalmic insert) 0.
